Results - Announcements
Dr Reddys Laboratories Ltd share price ticked higher by 0.11% to Rs 1239.0 after the company's net profit jumped 109.64% to Rs 913.2 crore, while revenue from operations slightly gained 7.44% to Rs 8670.8 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 26.82 lakh crore, rising 3.59%. It has softened by 2.75% over last one week and softened by 2.21% in last one month while the market capitalization of Dr Reddys Laboratories Ltd has slipped by 0.60% and 6.24% in the same period respectively.
Profit before tax (PBT) of Dr Reddys Laboratories Ltd stood at Rs 1227.6 crore in Q3 FY26, plunging by 29.64% year-on-year, and rallying 121.87% quarter-on-quarter. EBITDA came in at Rs 1574 crore, declining 6.62% YoY and jumping 211.64% sequentially.
Total expenses marginally dropped 3.63% to Rs 7493.9 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 1661.0 crore, growing marginally by 0.44% YoY, while employee benefits expense was at Rs 1611.9 crore, seeing a marginal contraction of 2.40% YoY.
For the TTM ended FY26, revenue from operations posted a slight growth of 3.19% to Rs 33593.3 crore, while net profit tanked by 27.38% to Rs 4157.6 crore, compared to previous TTM. EBITDA jumped by 780390% to Rs 5095.1 crore, and PBT plunged by 29.78% to Rs 5392.7 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 5673.7 crore in FY26, as against Rs 4642.8 crore in FY25.
Dr Reddys Laboratories Ltd declined by 3.19% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.37% during the same period.